TP-102
Not specified (within core therapeutic areas)
Phase 2bActive
Key Facts
About TechnoPhage
TechnoPhage is a clinical-stage biotech company developing novel therapeutics using a multi-platform approach centered on bacteriophage technology and biologics like recombinant single-domain antibodies. Its pipeline includes programs in infection, neurosciences, and ophthalmology, with a lead candidate, TP-102, having completed a Phase 2b trial. The company is privately held, pre-revenue, and has received national recognition in Portugal for its competitiveness and excellence, positioning it for potential Phase 3 development and partnerships.
View full company profile